

J.P. Morgan Healthcare Conference

Shire plc
January 10, 2012

Angus Russell
Chief Executive Officer



Our purpose

We enable people with life-altering conditions to lead better lives.

THE “SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company’s Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine products, as well as the ability to secure new products for commercialization and/or development; government regulation of the Company’s products; the Company’s ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company’s products; the Company’s ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company’s ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company’s filings with the Securities and Exchange Commission.

Delivering value in a challenging environment



Shire's business model has been the key to our financial success

Business Model

- Specialty biopharmaceutical company with expanding global reach
- Treatment of symptomatic diseases
- Operating leverage through efficient commercial infrastructure
- Growth through licensing, acquisition, and focused internal product development
- Focus on projects with relatively low risk and strong IP protection

Financial Impact 2003-2010

	Growth	CAGR
Total revenues	235%	16%
EBITDA	198%	15%



To be as brave as the people we help.

Shire is comprised of decentralized business units

Acquisition of ABH adds a strategic platform in Regenerative Medicine



To be as brave as the people we help.

HGT highlights



- ✓ Self-admin for acute HAE attacks approved by European Commission
- ✓ Approved and launched in the US with self-administration for acute attacks of Hereditary Angioedema in adults
- ✓ Strong product demand and market access since launch



- ✓ Ex-US market share increased to 81%, driven by switch and new patients
- ✓ Completed BLA submission in US
- ✓ 46% growth in revenues vs YTD Sept 2010



- ✓ Sharp increase in demand created by Cerezyme shortage
- ✓ 123% growth in revenues vs YTD Sept 2010



- ✓ European approval received for purification of REPLAGAL in new Lexington manufacturing facility
- ✓ Submitted regulatory filings with both the EMA and the FDA for the production of VPRIV in new Lexington manufacturing facility
- ✓ Inspection scheduled for January 2012



Pipeline

- ✓ Intrathecal programs progressing well
- ✓ Initiating natural history study in Sanfilippo B



To be as brave as the people we help.

Specialty Pharma highlights



- ✓ US Rx market share increased to 21%*
- ✓ Maintenance of remission claim added to label in US and Canada



- ✓ US licensing rights agreed with Janssen Pharmaceutica N.V.
- ✓ Additional European launches planned



- ✓ Adolescent indication launched in US
- ✓ Launched in Brazil as *VENVANSE*
- ✓ EU Marketing Application for *VENVANSE* accepted for review
- ✓ Potential Non-ADHD indications are progressing



- ✓ Launched indication for Co-Admin Adjunctive Therapy with Stimulant in the US
- ✓ Favorable increase in market share trends driven by new consumer marketing and adjunctive therapy with stimulant launch
- ✓ Enrolling EU pivotal phase 3 programs




To be as brave as the people we help.

2011 ADHD market growth primarily driven by Adults


YTD Nov'11

Overall ADHD Market Growth 10.7%



To be as brave as the people we help.

Vyvanse & Intuniv TRx growth outpaced ADHD market growth (10.7%) YTD Nov'11



To be as brave as the people we help.

VYVANSE new uses

Indication	Status
Major Depressive Disorder	<ul style="list-style-type: none"> Phase 3 studies initiated in Q4 2011: 3 controlled, short-term trials and 1 open-label long-term trial <ul style="list-style-type: none"> - Enrollment ~ 24 months, Treatment: 4 to 12 months, depending on trial - Final submission expected to include ~1,500 subjects
Excessive Daytime Sleepiness	<ul style="list-style-type: none"> Completing health authority interactions regarding potential for comparative labeling to enable optimal commercial positioning
Negative Symptoms in Schizophrenia	<ul style="list-style-type: none"> Positive health authority and global thought leader response to current data set Given tolerability in previous trial (highest VYVANSE doses), exploring risk-benefit profile of a higher dose range prior to initiating Phase 3 to enable optimal clinical use Will determine clinical pathway 1H12
Binge Eating Disorder	<ul style="list-style-type: none"> Phase 2 trial enrolment completed Expected data availability 1H12

Regenerative Medicine highlights



- ✓ \$50 million net sales in first full quarter as part of Shire*
 - 27% increase vs Q3 2010
 - Approximately 6% market share of addressable patient population
 - ✓ Finalizing strategy for infrastructure necessary to increase manufacturing capacity
 - ✓ Among U.S. residents aged 65 years and older, 10.9 million, or 26.9%, had diabetes in 2010**
-


* Shire acquired DERMAGRAFT through its acquisition of ABH on 28 June 2011

** Source: Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011



To be as brave as the people we help.

Investing to deliver growth now and into the future



To be as brave as the people we help.

2012 Key events

Lexington manufacturing plant approval for VPRIV

Potential REPLAGAL US approval

LIALDA diverticular disease Phase 3 data

VYVANSE binge eating disorder Phase 2 data

Potential DERMAGRAFT Canadian approval

Potential VENVANSE EU approval

Sanfilippo A and Hunter Intrathecal program updates

Strategy continues to deliver

Balanced product portfolio delivering excellent financial performance

Investing in promising pipeline opportunities

Delivering valuable and innovative treatments to meet the changing healthcare environment

Helping patients lead better lives

Q & A Breakout Olympic Room



Our purpose

We enable people with life-altering conditions to lead better lives.